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Summary
Somatic hypermutation (SHM) and class switch re-
combination (CSR) are initiated by activation-induced
cytidine deaminase (AID), which preferentially deami-
nates deoxycytidines at WRC (W = A/T, R = A/G) motifs
in vitro. Themechanisms responsible for targetingAID
and for organizing the queue of enzymes involved in
vivo have been elusive. Here, we examined point mu-
tant knockin Msh6 mice (Msh6TD/TD), which lack the
second phase of SHM but retain all the proteins in-
volved, and found that AID was frequently targeted to
non-WRC motifs. Unexpectedly, by comparing SHM
and CSR in wild-type, Msh6TD/TD, and age-matched
Msh62/2 mice, we discovered that the presence of
Msh6 protein influenced the AID targeting in phase
one of SHM and mediated the proper targeting of re-
combination sites in CSR in vivo. Our data suggest
that Msh6 plays a scaffolding role in the first phase of
SHM, in addition to its enzymatic role in the second
phase of SHM.
Introduction
SHM and CSR are both required to generate antibodies
that have sufficient affinity and range of effector func-
tions to protect us from environmental pathogens. In
SHM, point mutations are introduced into the variable
(V) regions of heavy and light chain genes that encode
the antigen binding site, resulting in higher affinity anti-
bodies (Barreto et al., 2005; Li et al., 2004c; Maizels,
2005). In CSR, double-stranded breaks (DSBs) are intro-
duced into the donor m and downstream g, 3, and
a switch regions that are 50 to each constant region to
trigger recombination (Chaudhuri and Alt, 2004; Li
et al., 2004c; Manis et al., 2002), which allows each V
region to be expressed with many different constant re-
gions and to carry out different effector functions. Both
SHM and CSR are initiated by AID (Martin et al., 2002;
Muramatsu et al., 1999, 2000; Petersen-Mahrt et al.,
2002; Ramiro et al., 2003; Revy et al., 2000; Yoshikawa
et al., 2002). AID has been shown to be a single-stranded
DNA deaminase in vitro (Bransteitter et al., 2003; Chaud-
huri et al., 2003; Dickerson et al., 2003; Pham et al., 2003;
Sohail et al., 2003), acting on deoxycytidine (dC) prefer-
entially at WRC motifs (Chaudhuri et al., 2004; Pham
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(M.D.S.)et al., 2003) to generate dG:dU mismatches (G:U mis-
match). The underlined letter represents the nucleotide
deanimated by AID. The resulting dU can be replicated
to produce transition mutations in the immunoglobulin
(Ig) genes or be removed by uracil-N-glycosylase (UNG),
creating abasic sites that can then be bypassed by
error-prone DNA polymerases to generate transition
and transversion mutations (Di Noia and Neuberger,
2002; Petersen-Mahrt et al., 2002). AID and UNG are
responsible for what has been called the first phase of
SHM, and all the mutations created during this phase
are at G:C bases and are thought to reflect the direct
targets of AID (Rada et al., 2004).
In the second phase of SHM, the G:U mismatches
generated by AID are recognized by a heterodimer of
the MutS homology proteins Msh2 and Msh6 (Li et al.,
2004c). Both Msh2 and Msh6 contain ATPase motifs
that convert ATP and ADP, which is essential for mis-
match repair (MMR). With the recruitment of additional
MMR proteins, such as MLH1, PMS2, and exonuclease
1 (Exo1), the DNA strand containing the G:U mismatch
is excised and then resynthesized by the error-prone
translesional polymerase eta (pol h) and perhaps other
error prone polymerases (Masuda et al., 2005; Zan
et al., 2005). This results in the introduction of mutations
at A:T bases (A:T mutations) that in vivo constitute ap-
proximately half of the mutations seen in V regions.
Thus, loss of the second phase of SHM should leave
only mutations at G/C bases that are targeted by AID
in the first phase of SHM (Martomo et al., 2004). Indeed,
there are very few A:T mutations in the V regions in mice
deficient in Msh2 (Frey et al., 1998; Martin et al., 2003;
Phung et al., 1998; Rada et al., 1998) or Msh6 (Li et al.,
2004b; Martomo et al., 2004; Wiesendanger et al., 2000)
and in mice (Delbos et al., 2005; Martomo et al., 2005) or
patients deficient in pol h (Rogozin et al., 2001; Zeng
et al., 2001). The heterodimer of Msh2/Msh6 stimulates
the catalytic activity of pol h in vitro (Wilson et al.,
2005), suggesting that, in the second phase of SHM,
Msh2/Msh6 and pol h coordinate to generate mutations
on both sides of the initial dU lesion. In fact, pol h has
a biochemical property of generating mutations at A:T
bases (Pavlov et al., 2002). In addition to these proteins
involved in SHM, it has been recently shown that the
ectopic expression of NBS1 accelerated SHM in the
Ramos Burkitt’s lymphoma cell line, suggesting that it
promotes DNA cleavage and/or mutagenic repair of le-
sions initiated by AID (Yabuki et al., 2005). Indeed, puri-
fied recombinant MRE11/RAD50 cleaves at abasic sites
in vitro (Larson et al., 2005a).
There are suggestive data that MMR proteins do not
exclusively function in the second phase of SHM. For ex-
ample, mice genetically deficient in Msh6, the heterodi-
meric partner of Msh2, not only had a loss of the second
phase of SHM but also a more restricted targeting of G:C
in the V region (Martomo et al., 2004) than Msh22/2/
UNG2/2 mice (Rada et al., 2004). In addition, it has re-
cently been shown that the Msh2/Msh6 heterodimer
binds with high affinity to DNA structures formed within
transcribed S regions and mediates their synapse
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physical presence of Msh6 protein might provide a scaf-
fold or participate in protein complexes that are impor-
tant in the regulation and recruitment of many proteins
involved in the first phase of the SHM process. In fact,
it has been suggested that the physical presence of
the UNG protein is more important than its enzymatic
activity (Begum et al., 2004a; Nagaoka et al., 2005). To
determine whether the presence of enzymatically inac-
tive Msh6 protein plays a role in SHM and CSR, we
have examined Msh6 knockin mice, which lack the mis-
match repair activity but produce wild-type levels of the
Msh6 protein (Yang et al., 2004). These mice, designated
as Msh6TD/TD, harbor a threonine (T) to aspartic acid (D)
mutation at position 1217 of Msh6. Although outside of
the ATPase domain of Msh6, this mutation is close to
where the ATPase domains of Msh6 and Msh2 interact
in the heterodimer (Yang et al., 2004). Biochemical stud-
ies showed that this mutation inhibits the ATPase activ-
ity of the Msh2/Msh6 dimer and ablates the ability of the
MMR complex to repair mismatches (Yang et al., 2004).
Although Msh6TD/TD mice have an increased incidence
of cancer, they are normal in their sensitivity to geno-
toxic agents and in signaling DNA damage triggered ap-
optosis (Yang et al., 2004).
Here, we report that more extended and diverse DNA
motifs are targeted by AID in Msh6TD/TD mice. In addi-
tion, Msh6TD/TD mice and age-matched Msh62/2 mice
exhibited different efficiencies and patterns of AID tar-
geting in SHM. Although Msh6TD/TD mice and Msh62/2
mice had a similar reduction in CSR, Msh6TD/TD mice in
which the mutant Msh6 protein was associated with
the switch regions exhibited normal targeting of recom-
bination sites, in contrast to Msh62/2 mice. Therefore,
we provide in vivo evidence for a role for Msh6 protein
in mediating the targeting AID to the V region in SHM
and to the switch recombination sites in CSR.
Results
Msh6TD/TD Mice Lack the Second Phase of SHM
We first compared the frequency and characteristics of
mutations in the V regions in fourMsh6TD/+ mice to three
littermate Msh6+/+ mice. The frequency of mutation was
similar between theMsh6TD/+ and wild-type mice (10.13
1023 and 10.2 3 1023, respectively). In addition, the de-
tailed mutation spectrum at A:T bases and at G:C bases
was indistinguishable in Msh6TD/+ mice and Msh6+/+
mice (Table S1 available in the Supplemental Data with
this article online). We therefore have pooled the results
of the wild-type and Msh6TD/+ littermates and labeled
them as controls in all of the subsequent experiments.
Because the semidominant cancer phenotype of this
T-D mutation was related to its interference with Msh3
function (Yang et al., 2004), and the loss of Msh3 had
no effect in SHM (Li et al., 2004b; Martomo et al., 2004;
Wiesendanger et al., 2000), the finding that Msh6TD/+
mice did not have a detectable phenotype in SHM was
expected.
As shown in Figures 1A and 1C, the percentage of the
Jh2-Jh4 introns that contained mutations (mutated
sequences) was approximately the same between
Msh6TD/TD mice and the littermate controls (50.5% ver-
sus 51.7%, p = 0.86), but the frequency of mutations(the total number of mutations seen divided by the total
number of nucleotides sequenced) in Msh6TD/TD mice
was reduced compared to the controls (4.9 3 1023 ver-
sus 10.23 1023, p < 0.0001). In addition, more than 90%
of mutations inMsh6TD/TD mice were at G:C bases, com-
pared to 46% in the controls (p < 0.0001) (the pooled re-
sults were representative of individual mouse mutation
spectrum), and a higher percentage of these were tran-
sition mutations in Msh6TD/TD mice (Figures 1B and 1C).
This spectrum of mutations was similar to that found in
five age-matched Msh62/2 mice examined at the same
time (Figures 1B and 1C), indicating that, like Msh62/2
mice, Msh6TD/TD mice also lack the second phase of
SHM. However, the percentage of mutated sequences
in Msh6TD/TD mice was significantly higher than in
Msh62/2 mice (50.5% versus 36.8%, p = 0.003), as was
the frequency of mutations (4.9 3 1023 versus 2.5 3
1023, p < 0.0001) (Figures 1A and 1C). Although the mu-
tation spectrum in Figure 1 was from the Peyer’s patches
of older mice, we obtained similar results from younger
mice (data not shown), indicating that these differences
were not attributed to age.
To obtain a second independent analysis of V region
mutations, we sequenced the Jh4 flanking region from
B cells harboring VhJ558-Jh4 rearrangements (from the
same sets of mice). This allowed us to use the CDR3 to
identify the clonal progeny of individual B cells within
each mouse and thus include repeated mutations in
our analysis if they arose from different B cell clones.
Like the Jh2-Jh4 intron region, the percentage of mu-
tated sequences in Msh6TD/TD mice (69.5%) was statis-
tically similar to the controls (57.9%) (Figures S1A and
S1C). The predominance of G:C mutations and transi-
tion mutations in this region from Msh6TD/TD mice
compared to control mice was comparable to that ob-
served in the Jh2-Jh4 intron (Figures S1B and S1C). In
addition, the percentage of mutated sequences and
the frequency of mutations in Msh6TD/TD mice were
again higher than in Msh62/2 mice (p < 0.0001 and
p < 0.0001, respectively), even though both sets of
mice showed a similar mutation spectrum (Figures
S1B and S1C). Therefore, in two different regions, we
saw the lack of second phase of SHM in Msh6TD/TD
mice. Furthermore, the presence of the point mutant
Msh6 protein increased the frequency of SHM as well
as the percentage of V region segments targeted for
mutation.
Msh6TD/TD Mice Exhibit a Focused Mutation Pattern
The distribution of mutations was analyzed by plotting
the mutability in Msh6TD/TD mice and the control mice
at each G:C position within the first 420 bases of the
Jh2-Jh4 region (Figure 1D). The control and Msh6TD/TD
mice shared some frequently mutated sites, e.g., 31G,
50C, 166C, and 237C, all of which are at WRC motifs
and are considered hot spots for AID mutations (Rogo-
zin and Diaz, 2004) (Figure 1D and Table S2, left). How-
ever, Msh6TD/TD mice had a more restricted pattern of
G:C mutations than the control mice, which had G:C
mutations distributed throughout the whole region (Fig-
ure 1D). Although Msh6TD/TD and Msh62/2 mice both
showed a more focused mutation pattern and shared
some sites of mutations, e.g., 29C, 31G, 49G, 50C,
165G, 166C, and 237C, a number of sites were mutated
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395Figure 1. Mutation Analyses from the Jh2-Jh4 Intron Region in Msh6TD/TD and Msh62/2 Mice
Data were obtained from seven control mice, six Msh6TD/TD mice, and five age-matched Msh62/2 mice.
(A) Pie charts depicting the percentage of mutated sequences with different numbers of mutations.
(B) The detailed mutation characterization from each mouse line. Identical mutations at the same position were only counted once in each
mouse.
(C) Comparison of mutation spectra. P value 1 compares the data from the control to those from Msh6TD/TD mice. P value 2 compares the data
from Msh6TD/TD to those from Msh62/2 mice. p < 0.05 is considered statistically significant.
(D) Mutation positioning for G:C bases between the control andMsh6TD/TD mice. The x axis is the 420 bp fragment corresponding to the germline
sequence X53774.1 (nucleotides 368–787). The y axis is the percentage of mutated DNA sequences.
(E) Mutation positioning for G:C bases between Msh6TD/TD and Msh62/2 mice. The s axis and y axis are defined as in (D).
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Mutated % P Value
WGW/WCW WGW/WCW
40 AATAGATTT 7.2 0 <0.0001 85 TGGAGTTTT 7.2 0.6 <0.01
47 TTTACTGCA 0.6 5.1 <0.01 159 TAAACTGTC 12.3 0 <0.0001
29 TATTCAGCT 5.6 5.1 0.84 242 TGGAGTCCC 7.2 0 <0.001
525 CTTAGTGAT 7.3 0 <0.001
102 TGCAGACTA 19.6 0 <0.0001
514 AGGAGAGCT 7.2 0.6 <0.01
203 ACATCTTTG 5.1 0 <0.01
77 CTTTGTTAT 12.3 2.8 <0.01
223 ATCTGTGTG 12.3 0 <0.0001
221 GAATCTGTG 0 5.6 <0.01
366 ATTAGTTGT 0 11.2 <0.0001
450 GGCACTTTC 0 9.0 0.0001
413 TACAGTATC 5.1 10.7 0.107
WGC WGC
136 GGGAGCCCC 6.7 0.7 <0.001 516 GAGAGCTGT 16.7 0.6 <0.0001
31 TTCAGCTTA 13.9 8.6 0.094 401 GACAGCATT 17.4 6.2 <0.01
165 CTCAGCTCC 11.7 7.6 0.18 94 CTGAGCATT 21.0 12.9 0.076
236 CTATGCTTT 7.8 1.4 <0.001 99 CATTGCAGA 31.9 10.1 <0.0001
343 GTTTGCTTA 9.6 1.0 <0.0001 448 GGGGCACTT 3.6 9.0 0.069
411 AAATGCATG 12.5 5.2 0.014 422 CGATGCATA 7.2 8.4 0.86
49 TACTGCATT 13.3 14.0 0.94
WGC WGC
32 TCAGCTTAA 13.9 5.8 <0.01 291 GATGCTAAA 35.5 9.0 <0.0001
166 TCAGCTCCC 13.3 12.1 0.79 100 ATTGCAGAC 10.9 2.2 <0.01
335 TGTGCCTGG 18.0 1.0 <0.0001 423 GATGCATAG 8.7 0 <0.0001
344 TTTGCTTAC 14.7 5.5 <0.01 95 TGAGCATTG 0 7.9 <0.001
237 TATGCTTTC 9.4 6.2 0.26 178 AGAGCCTTT 0.7 8.4 <0.01
380 TCTGCAGGT 1.5 9.7 0.001 578 GTTGCTGTC 0.7 11.2 <0.001
50 ACTGCATTT 7.2 7.9 0.93 517 AGAGCTGTC 5.1 5.6 0.97
WGG AWCC
97 GAAGGACTA 10.6 1.4 <0.0001 417 GTATCCGAT 7.2 0 <0.001
133 ATTGGGAGC 6.7 0 <0.0001 73 TAACCTTTG 3.6 19.7 <0.0001
221 CTAGGTCCC 7.2 0 <0.0001 72 TTAACCTTT 10.9 10.1 0.97
Others Others
216 TGCCGCTAG 7.8 0 <0.0001 112 TCTTGGATA 7.2 0.6 <0.01
138 GAGCCCCTG 5.0 0 <0.001 419 ATCCGATGC 7.2 0 <0.001
P value was defined to compare the data from Msh6TD/TD mice to those from Msh62/2 mice, using c2 test or Fisher’s exact test. p < 0.05 is con-
sidered statistically significant (bold). Gs or Cs in RGYW or WRCY hotspot motifs are bolded.more frequently in Msh6TD/TD mice than in Msh62/2
mice, e.g., 32C, 40G, 97G, 133G, 136G, 138C, 216G,
221G, 236G, 335C, 343G, 344C, and 411G (Figure 1E
and Table S2, left). These pooled results of positions
having mutations conformed well to individual mice.
To confirm these findings, we plotted G:C mutations
from the VhJ558-Jh4 rearranged Jh4 flanking region. A
similar focused G:C mutation pattern was observed in
Msh6TD/TD mice compared to the control mice (Fig-
ure S1D). The pattern of mutation distribution in
Msh6TD/TD mice also differed significantly from Msh62/2
mice (p < 0.0001) (Table S2, right, and Figure S1E).
Some sites were mutated in the control, Msh6TD/TD, and
Msh62/2 mice, e.g., 73C, 77G, 94G, 401G, and 517C. A
number of sites were more frequently mutated in the
Msh6TD/TD mice than in Msh62/2 mice, e.g., 85G, 99G,
100C, 102G, 159C, 223G, 242G, 291C, 423C, 514G,
516G, 525G, etc., and vice versa (Table 1, Figure S1E,
and Table S2, right).Motifs Targeted for Mutation by AID in Msh6TD/TD
Mice and Msh62/2 Mice
Because Msh6TD/TD and Msh62/2 mice lack the second
phase of SHM, the mutated G:C bases in these mice
should reflect the in vivo targeting of AID (phase 1).
Although the Msh62/2 mice reflect the primary targets
of AID when there is no Msh6 protein available, the
Msh6TD/TD mice retain wild-type levels of the Msh6 pro-
tein and should reveal the primary AID targets in vivo
when the Msh6 protein is present. A number of G:C mu-
tations in both Jh2-Jh4 and Jh4 flanking regions of the
control mice were in WRC/GYW (W = A/T, R = A/G,
and Y = C/T) motifs (Table S2 and data not shown), as
has been reported by others (Shapiro et al., 1999). How-
ever, inMsh6TD/TD mice, mutations were focused mainly
at WGW/WCW, WGC, WGC, WGG, and AWCC motifs
(Table 1). For WRC motifs, shown to be preferentially
targeted by semipurified AID in vitro, we observed that
these motifs were mainly at WGC. For GYW, the
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were mainly at WGC/GCW, except 136G in the Jh2-Jh4
intron region and 448C in the Jh4 flanking region. Most
WCW/WGW motifs were not WRC/GYW motifs, e.g.,
29C and 40G in the Jh2-Jh4 region and 102G, 203C,
223G, 242G, 514G, and 525G in the Jh4 flanking region.
For AWCC motifs, 72C belongs to WRC, but 73C and
417C in the Jh4 flanking region do not. Furthermore, in
the Jh2-Jh4 region, we observed that WGG motifs
such as 97G, 133G, and 221G were highly mutated, sug-
gesting these are favorable targets for AID in the
Msh6TD/TD mice even though they were not at WRC/
GYW and were not targeted in Msh62/2 mice (Table
S2, left, and Table 1, left).
We observed striking differences in AID targeting effi-
ciencies between Msh6TD/TD mice and Msh62/2 mice. In
the Jh2-Jh4 region, although there were a few motifs
that were targeted approximately equally in both, e.g.,
positions at 29C, 31G, 49G, 50C, 165G, 166C,
and 237C (most of these fall in AGCT or TGCA motifs)
(Figure 1E and Table 1, left), the targeting efficiency dif-
fered drastically between Msh6TD/TD and Msh62/2 mice
at a number of motifs. WGG motifs were almost exclu-
sively targeted in Msh6TD/TD, but not in Msh62/2 mice.
WGC motifs at positions 136, 236, 343, and 411 as well
as WGC motifs at positions 32, 335, and 344 were favor-
ably targeted in Msh6TD/TD mice (Figure 1E and Table 1,
left). In the Jh4 flanking region, a number of WGW/WCW
motifs, AWCC at position 417, WGC motifs at positions
99, 401, and 516, and WGC motifs at positions 100, 291,
and 423, were more efficiently targeted in Msh6TD/TD
mice (Figure S1E and Table 1, right), whereas WGC
motifs at positions 95, 178, and 578 were favorably tar-
geted in Msh62/2 mice. Moreover, an AACC motif at
position 73, which does not belong to WRC, was the
best target in Msh62/2 mice, but not frequently targeted
in Msh6TD/TD mice. In summary, the AID targeted motifs
that were least affected by the presence of Msh6 protein
were mostly located at AGCT or TGCA. WGG and other
‘‘cold-spot’’ motifs (Table 1, bottom panels) were exclu-
sively targeted by AID inMsh6TD/TDmice, but notMsh62/2
mice. Taken together, these differences in targeting sug-
gest that the presence of Msh6 protein affects the effi-
ciency and changes the motifs targeted by AID in vivo.
Class Switching in Msh6TD/TD Mice
To further understand the role of Msh6 in generating
protective antibodies, we compared various aspects of
CSR between Msh6TD/TD and Msh62/2 mice. Based on
cell counts and CFSE profiles, in vitro-stimulated splenic
B cells from Msh6TD/TD mice proliferate normally (data
not shown). Like Msh62/2 mice (Li et al., 2004b),
Msh6TD/TD mice exhibited w5-fold reduction in switch-
ing to IgG3 (Figure 2A) andw2-fold reduction in switch-
ing to IgG1 (Figure 2B). In addition, Msh6TD/TD mice did
not exhibit a change in the frequency of blunt junctions,
1–2 nt andR5 nt microhomologies, and various sizes of
insertions, although they had fewer 3–4 nt microhomol-
ogies (p < 0.05), compared to the control littermates
(Figure 2C). The complete alignment of Sm-Sg3 junctions
from these mice is presented in Table S3. Unlike our pre-
vious studies, which showed thatMsh62/2mice differed
from their wild-type control littermates in the location of
their switch junctions within Sm (residues 451–760) andwithin Sg3 (residues 2301–2400) (Li et al., 2004b),
Msh6TD/TD mice were similar to their wild-type control lit-
termates in these features (Figures 2D and 2E). Similarly,
there was also no change in the targeting to the GAGCT/
GGGGT consensus motifs in Sg3 between Msh6TD/TD
mice and the wild-type control mice (Figure 2F). These
results suggest that both the mismatch repair activity
and the physical presence of the Msh6 protein are in-
volved in efficient and proper targeting of CSR.
We used chromatin immunoprecipitation (ChIP) anal-
yses of primary splenic B cells stimulated to switch to
IgG1 to determine whether the Msh6 protein was pres-
ent in the switch regions. Indeed, Msh6 was associated
with both the donor Sm and the recipient Sg1 regions
during CSR in Msh6TD/TD mice, but not in Msh62/2
mice (Figure 2G). These results are consistent with the
finding that Msh2 was associated with S regions in
CSR (Larson et al., 2005b). The regions that were exam-
ined with the ChIP assay were associated with g-H2AX,
which is involved in repairing DSBs. RNA polymerase II
(RNAP II) and Exo1 also were associated with both re-
gions in Msh6TD/TD and Msh62/2 mice. We did not ob-
serve the association of Msh6 with the Sg3 region in
Msh6TD/TD mice (Figure 2G), consistent with the fact
that under the stimulation of LPS and IL4 cells predom-
inantly switched to IgG1, but not to IgG3.
We also analyzed the mutation frequency and spectra
obtained from the recombined switch sequences in
Msh6TD/TD mice when primary B cells were stimulated
to switch to IgG3. When we recovered the recombined
switch sequences by PCR and obtained various sizes
of Sm and Sg3 segments, we observed many mutations
in these sequences. These mutations seemed to be dis-
tributed throughout the regions sequenced (data not
shown). Although sequences near the breakpoint often
harbored slightly more mutations, this was not statisti-
cally significant. In the recombined Sm region, the per-
centages of mutations at A:T bases and G:C bases in
the wild-type control and Msh6TD/TD mice were similar,
but there was a significant increase in transition G:C
mutations in Msh6TD/TD mice (Figures 3A and 3B). In ad-
dition, the mutation spectra between Msh6TD/TD and
Msh62/2 mice were similar, and the frequencies of re-
combined Sm mutations in wild-type control, Msh6TD/TD,
andMsh62/2mice were similar (Figure 3B), which differs
from what was observed in the Jh2-Jh4 and Jh4 flanking
regions for SHM (Figures 1 and Figure S1). In addition,
Msh6TD/TD and Msh62/2 mice all had 20%–30% A:T mu-
tations in their recombined Sm segments, which is also
different from SHM. When we examined these charac-
teristics in the recombined Sg3 region, we observed
similar results to those in the recombined Sm region
(data not shown).
Discussion
In SHM of the V region, G:C mutations are frequently
found in RGYW/WRCY motifs or the somewhat broader
DGYW/WRCH motifs (Rogozin and Diaz, 2004) in vivo.
This observation has been used to deduce the motifs
that are initially acted on by AID. Biochemical evidence
for this has been obtained by showing that AID has an
intrinsic preference for deaminating C in WRC motifs
(Chaudhuri et al., 2004; Pham et al., 2003), an activity
Immunity
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Data were obtained from seven littermate control mice (four wild-type and three heterozygous) and sixMsh6TD/TD mice.Msh62/2mice data were
published before (Li et al., 2004b) and shown here for comparison purposes.
(A) The effect on IgG3 switching stimulated by LPS. The switching to IgG3 in control B cells was defined as 100% (hatched bar). The relative
percentage of switching, compared to the control, in Msh6TD/TD and Msh62/2 mice is shown. The background switching to IgG1 (white bars)
is also shown. Error bars are shown to represent the standard deviation.
(B) The effect on IgG1 switching stimulated by LPS plus IL4. The switching to IgG1 in control B cells was defined as 100% (white bar). The relative
percentage of switching, compared to the control, inMsh6TD/TD and Msh62/2mice is shown. The background switching to IgG3 (hatched bar) is
also shown. Error bars are shown to represent the standard deviation.
(C) Characteristics of Sm-Sg3 switch junctions between the control and Msh6TD/TD mice. Except for 3–4 nt, there was no statistically significant
difference between the control and Msh6TD/TD mice in the percentage of blunt junctions, microhomologies, and insertions.
(D) Comparison of Sm 451–760 positioning effect between Msh6TD/TD and Msh62/2 mice. Homozygous mice are depicted as gray bars, and their
respective controls are depicted as white bars. The p value between Msh62/2 mice and their control is 0.0006, whereas the p value between
Msh6TD/TD mice and their control is 0.26.
(E) Comparison of Sg3 2201–2400 positioning effect betweenMsh6TD/TD andMsh62/2mice. The p value betweenMsh62/2mice and their control
is 0.035, whereas the p value between Msh6TD/TD mice and their control is 0.95.
Msh6 Affects AID Targeting in Hypermutation
399Figure 3. Comparison of Recombined Switch Region Mutations Derived from LPS-Stimulated Primary B Cells from Msh6TD/TD Mice and
Msh62/2 Mice
(A) Comparison of switch region mutations from the recombined Sm in Msh6TD/TD mice and in wild-type mice.
(B) Detailed analyses of recombined Sm region mutations from Msh6TD/TD mice, Msh62/2 mice, and wild-type mice.
Data were obtained from four Msh6+/+ littermate mice and six Msh6TD/TD mice. Data from Msh62/2 mice were published previously (Li et al.,
2004b) and used for comparison purpose. P value 1 is defined as to compare the data from the control to those from Msh6TD/TD mice; p value
2 is defined as to compare the data from Msh6TD/TD mice to those of Msh62/2mice. P values were calculated by using c2 test. p < 0.05 was con-
sidered statistically significant (bold face).which is stimulated by RPA (Chaudhuri et al., 2004) and
by PKA phosphorylation (Basu et al., 2005; Pasqualucci
et al., 2005). Although these biochemical studies corre-
late well with G:C mutations in vivo, it is unclear what
the primary AID targets are because there are two
phases in SHM, hampering identification of where all
of the G:C mutations originate from. Phase one reflects
the direct AID targets, whereas phase two not only gen-
erates mutations at A:T bases but could, in principle,
also generate mutations at G:C bases that do not result
from direct AID targeting (Reynaud et al. [2003] and see
below). The increased focusing of AID-induced muta-
tions in both Msh6TD/TD and Msh62/2 mice suggests
that some of the G:Cs that are mutated in wild-type
mice are not the primary targets of AID in vivo (Martomo
et al., 2004). Because Msh62/2mice not only lack phase
two of SHM but also the Msh6 protein, it would be more
useful to examine the primary targeting motifs for AID in
an environment in which all of the proteins involved are
retained but phase two is missing. The point mutant
Msh6TD/TD mice in which the second phase of SHM is
blocked and the point mutant protein is still present at
wild-type levels and forms dimers with Msh2 (Yang
et al., 2004) provide a good candidate for this purpose.
Using this mouse model, our data suggest that WGW/
WCW, WGG, WGC, and AWCC motifs are the primary
AID targets. A number of mutations at WGC and WGC
motifs suggest that WGC paired with its complementarystrand GCW is a favorable substrate in vivo, in which
dCs on both strands can be targeted by AID simulta-
neously. In addition, the majority of mutations at
WGW/WCW motifs are located at Gs in the Jh4 flanking
region, suggesting that Cs on the transcribed strand in
such motifs are preferentially deaminated by AID. The
difference between our data and those from in vitro
studies could reflect the presence of SHM-specific AID
cofactors in vivo. In fact, it has been reported that N-ter-
minal and C-terminal AID mutants have different effects
in SHM and CSR (Barreto et al., 2003; Shinkura et al.,
2004; Ta et al., 2003), suggesting that SHM-specific
and CSR-specific complexes exist (Li et al., 2003).
It has been suggested that all of the mutations at G:C
bases were produced during the first phase of SHM,
whereas only A:T mutations were produced during the
second phase (Rada et al., 2004). However, in our
Msh6TD/TD mice, we observed that G:C mutations ap-
peared only at certain positions, whereas in the control
mice, G:C mutations were distributed throughout the
whole region (Figure 1D and Figure S1D). These results
clearly argue that there are G:C mutations, as well as
A:T mutations, generated through MMR-mediated sec-
ond phase of SHM. This is true in both Msh6TD/TD mice
and Msh62/2 mice.
Although Msh6TD/TD mice resembled Msh62/2 mice in
that there was no phase two and AID was targeted to
morerestrictedsites, theiroverallAIDtargetingefficiencies(F) Comparison of GAGCT/GGGGT consensus targeting in Sg3 between Msh6TD/TD and Msh62/2 mice. The p value between Msh62/2 mice and
their control is 0.001, whereas the p value between Msh6TD/TD mice and their control is 0.21.
(G) Representative ChIP results showing that the Msh6 protein is associated with switch regions inMsh6TD/TD mice, but not inMsh62/2mice from
B cell stimulated with LPS plus IL4. Semiquantitative PCR was carried out at 4-fold serial dilutions. Control Ab stands for the control antibody,
either polyclonal rabbit IgG or rabbit anti-b-actin.
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400and patterns of mutation were different (Figure 1E,
Figure S1E, Table 1, and Table S2). These results argue
that Msh6 influences the primary targeting of AID, either
directly or indirectly, and thus plays a more diverse role in
AID targeting than had been previously appreciated. This
could occur in at least three different ways. First, the mis-
match repair activity is essential for the second phase of
SHM (Figures 1B and 1C and Figures S1B and S1C), con-
sistent with ours (Martin et al., 2003) and others previous
observations. Second, Msh6 directly or indirectly in-
creases the efficiency of AID targeting to the V region,
as manifested by a lower mutation frequency and a lower
percentage of mutated sequences inMsh62/2mice (Fig-
ures 1A and 1C and Figures S1A and S1C), presumably
because AID was less efficiently targeted to a number
of motifs inMsh62/2mice (Figure 1E, Figure S1E, and Ta-
ble 1). Third, Msh6 changes the AID targeting pattern.
Some motifs that were not frequently targeted in
Msh6TD/TD mice, e.g., 73 AACC, 366 TAGT, 450 CACT,
578 TGCT, etc. (Table 1, right) were very efficiently tar-
geted in Msh62/2 mice and vice versa. These results,
along with the studies of AID proteins with mutations or
deletions (Barreto et al., 2003; Bransteitter et al., 2004;
Shinkura et al., 2004; Ta et al., 2003), raise the possibility
that the Msh6 protein could be one of the components in
the SHM-specific AID complex. It is possible that Msh2/
Msh6 with associated proteins preferentially binds to
certain motifs first and that the recruitment of an AID-
SHM complex to these motifs is facilitated directly or in-
directly by Msh6. Such a role for Msh6 in the first phase of
SHM to influence AID targeting would be an efficient way
to somatically hypermutate the V region, because once
a single G:U mismatch is generated, more mutations
could be readily generated via the second phase of
SHM. In fact, in human V regions, many of the initial
AID-induced mutations in CDR1 do not result in amino
acid replacements (Zheng et al., 2005), so the mutations
at A:T and G:C bases that arise during the second phase
of SHM are very important in producing higher affinity an-
tibodies. However, when we extensively carried out im-
munoprecipitation (IP) experiments with lysates from
Ramos cells, stimulated splenic B cells that express
high levels of AID, and 293T cells expressing two differ-
ent versions of tagged AID, we did not observe any evi-
dence for the existence of a stable complex that con-
tained both Msh6 and AID (Z.L., C.Z., M.D.I.-U., and
M.D.S., unpublished data).
It is still possible that there could be an interaction be-
tween AID and Msh6 that is transient, weak, or requires
additional proteins, such as those that are presumed to
bind to the N- and C-terminal ends of AID (Barreto et al.,
2003; Bransteitter et al., 2004; Shinkura et al., 2004; Ta
et al., 2003). However, we favor the hypothesis that the
effect of Msh6 on the efficiency and targets of AID is in-
direct. For example, binding of Msh2/Msh6 to G:U mis-
matches could potentially stimulate AID to act at other
C sites; Msh6 could be involved in efficiently creating
or maintaining certain DNA structures to allow AID to
gain access to single stranded DNA region, which would
be at least partially consistent with the finding by Larson
et al. (2005b), and/or Msh6 might be a scaffold that re-
cruits factors important for activation or modification
of some proteins, which in turn more efficiently activate
or target AID.Msh6 is important for efficient CSR, as manifested by
the fact thatMsh6TD/TD andMsh62/2mice showed a sim-
ilar reduction in switching to IgG3 and IgG1 (Figures 2A
and 2B). Because the aberrant targeting to S regions
was not seen in Msh6TD/TD mice (Figures 2D–2F) but
was seen in Msh62/2 mice, we conclude that the Msh6
protein itself is important for targeting switch recombi-
nation sites. In fact, ChIP experiments showed that the
Msh6 protein was associated with switch regions in
Msh6TD/TD mice (Figure 2G). The Msh6 protein could
contribute to targeting switch recombination sites by
processing G:U mismatches to generate and/or resolve
DSBs. Furthermore, it has recently been shown that
Msh2/Msh6 can bind to and form synapses between
G4 DNA structures in switch regions even in the absence
of mismatches (Larson et al., 2005b), again suggesting
that Msh6 has a broader role than only recognizing
and repairing G:U mismatches.
We consistently observed that the mutation frequency
from recombined switch regions in Msh6TD/TD and
Msh62/2 mice did not differ from the wild-type control
mice (Figure 3B), in contrast to the decrease in muta-
tions in the Jh2-Jh4 intron and Jh4 flanking regions of
SHM in the same mice (Figure 1 and Figure S1), suggest-
ing that MMR proteins are not required to generate mu-
tations in CSR. In addition,Msh6TD/TD andMsh62/2mice
showed few A:T mutations during SHM (Figure 1 and
Figure S1) but a high proportion of A:T mutations in
the recombined switch regions (Figure 3), even though
switch regions have a higher percentage of G:C bases
than the V region. These results suggest that there are
mechanistic differences in resolving the G:U mis-
matches in S regions for CSR and in the V region for
SHM. In particular, in the V region, G:U mismatches
can be recognized by mismatch repair to initiate the sec-
ond phase of SHM to generate additional mutations. It is
conceivable that this may also occur in the S regions,
but during CSR, A:T and G:C mutations can also occur
when DSBs are being repaired by NHEJ in the S regions.
In addition, some single-stranded breaks, which are
generated in the course of CSR but fail to form DSBs,
could be refilled by error-prone polymerases to generate
mutations at A:T bases as well as G:C bases. One could
imagine that this refilling process is independent of
mismatch repair. Nevertheless, in CSR and in SHM,
Msh6TD/TD mice and Msh62/2 mice have no mismatch
repair activity so that G:U mismatches are more likely
to be replicated to generate more transition mutations.
In summary, we presented in vivo evidence that
WGW/WCW, WGC, and WGG are the primary targets
for AID in SHM and that the physical presence of Msh6
proteins influences the targeting of AID in SHM and the
proper targeting of switch recombination sites in CSR.
Our data suggest that Msh6 might be one of SHM and/
or CSR-specific factors or might interact with such a
factor. Our results will allow us and others in the field
to explore how AID targeting is regulated and coordi-
nated with other proteins.
Experimental Procedures
Mice
The Msh6TD/TD mouse line was generated and reported previously
(Yang et al., 2004). Msh6TD/TD mice used in this study were
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401backcrossed to C57BL/6 mice for at least four generations and were
housed in a pathogen-free facility.Msh62/2mice were reported pre-
viously (Edelmann et al., 1997; Li et al., 2004b; Wiesendanger et al.,
2000). All mouse experiments were approved by the Albert Einstein
College of Medicine Animal Use Committee.
Assay SHM
Aged mice around 11.5–12 months old were sacrificed and Peyer’s
patches were isolated from outside of the small intestine. PNAhigh
B220+ germinal center B cells were obtained as described (Bardwell
et al., 2003, 2004; Martin et al., 2003). Three wild-type, four heterozy-
gous, and six homozygous littermate Msh6TD/TD mice were ana-
lyzed. Five age-matched Msh62/2 mice were also included in this
study. The Jh2-Jh4 intron region was amplified, and the PCR prod-
ucts were gel purified, cloned, and sequenced. VhJ558-Jh4 rear-
rangements were amplified by using the primers as described (Jolly
et al., 1997). The PCR was carried out at 95ºC, 30 s; 67ºC, 1 min 30 s;
and 72ºC, 2 min with hot start using Pfu-turbo polymerase for 34 cy-
cles. The VhJ558-Jh4 PCR products were gel purified, cloned, and
sequenced.
In Vitro Switching Assay
Mice between 4 and 10 weeks old were used to examine the rate of
CSR. Four wild-type, three heterozygous, and six homozygous litter-
mate Msh6TD/TD mice were analyzed. Splenic B cells were obtained
and then stimulated with 50 mg/ml LPS (Sigma) or 50 mg/ml LPS and
50 ng/ml rIL-4 (R&D) for 4 days as described (Li et al., 2004b). Sur-
face antibody IgM and IgG were stained and analyzed with a FACS-
Calibur (Becton-Dickinson). FACS analysis was performed by using
the FlowJo software package (Treestar), as described previously (Li
et al., 2004b).
ChIP Analyses
Splenic B cells were stimulated with LPS plus IL4 as described.
Forty-eight hours after stimulation, cells were washed once with
PBS and stained with B220-PE and IgG1-FITC. Cells were then fixed,
FACSorted, lysed, and sonicated as described (Begum et al., 2004b)
except that 10 mM sodium pyrophosphate was added in cell lysis,
sonication, and later immunoprecipitation steps, as reported before
(Li et al., 2004a). Anti-RNAP II and anti-Msh6 antibodies were pur-
chased from Santa Cruz Biotechnology (Sc-899 and Sc-10798, re-
spectively). Rabbit polyclonal anti-g-H2AX antibody was purchased
from Upstate. Anti-Exo1 antibody was described previously (Bard-
well et al., 2004). Semiquantitative PCR was carried out with primers
for Sm, Sg1, and Sg3 as previously described (Li et al., 2004a).
Statistical Analyses
c2 test was used to compare the two sets of raw data. When we
compared the overall mutation distributions between two different
kinds of mice, only the positions in which at least one kind of mice
had mutations were considered. In the format of 2 3 2, if there
was a number less than five, two-tailed Fisher’s exact test was
used. Statistical significance was defined as p < 0.05.
Supplemental Data
Supplemental Data include one figure and three tables and can be
found with this article online at http://www.immunity.com/cgi/
content/full/24/4/393/DC1/.
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